Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Last trade$3.35
Day change-$0.17 (-4.83%)
Day range$3.32 – $3.68
Volume682,463
Market cap$228M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$227.97M
Price / earnings
—
Price / book
1.35×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.31×
Profitability
Earnings per share
-$1.03
Return on assets
-36.43%
Return on equity
-39.43%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
13.97×
Quick ratio
13.97×
Cash ratio
5.4×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$61.81M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IMRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$5.06M
$5M
$4.68M
$4.49M
$4.51M
$4.3M
$4.01M
$3.69M
Research and development
$20.72M
$14M
$10.65M
$9.25M
$10.87M
$10.45M
$11.47M
$14.86M
Total operating expenses
$25.79M
$19M
$15.34M
$13.75M
$15.38M
$14.76M
$15.48M
$18.56M
Operating income
-$25.79M
-$19M
-$15.34M
-$13.75M
-$15.38M
-$14.76M
-$15.48M
-$18.56M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$24.19M
-$17.27M
-$13.46M
-$11.58M
-$14.96M
-$14.43M
-$15.05M
-$18.05M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$24.19M
-$17.27M
-$13.46M
-$11.58M
-$14.96M
-$14.43M
-$15.05M
-$18.05M
Net income attributable to common shareholders
-$24.19M
-$17.27M
-$13.46M
-$11.58M
-$14.96M
-$14.43M
-$15.05M
-$18.05M
EBITDA
-$25.69M
-$18.91M
-$15.25M
-$13.67M
-$15.29M
-$14.67M
-$15.39M
-$18.46M
Basic earnings per share
-$0.37
-$0.27
-$0.21
-$0.18
-$0.38
-$0.40
-$0.42
-$0.58
Diluted earnings per share
-$0.37
-$0.27
-$0.21
-$0.18
-$0.38
-$0.40
-$0.42
-$0.58
Recent news
Company coverage with links to the original publishers.
Immuneering Corporation announced preclinical data demonstrating that atebimetinib, a MEK inhibitor, enhances PD-1 checkpoint blockade in RAS mutant tumor models. The findings support the company's plans to conduct a Phase 2 study combining atebimetinib with PD-1 blockade in lung cancer patients. The poster will be presented at the SITC 41st Annual Meeting in November 2026.
Following an FDA approval of a second-line pancreatic cancer treatment, Immuneering Corporation reaffirmed its focus on first-line metastatic pancreatic cancer patients. The company is enrolling patients in its Phase 3 MAPKeeper 301 trial evaluating atebimetinib combined with chemotherapy. Previous Phase 2a data showed 17.3-month median overall survival with manageable side effects, with 84% of patients maintaining or gaining weight at three months.
U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose on better-than-expected earnings.
Immuneering Corporation announced positive Phase 2a trial results showing 64% overall survival at 12 months for atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, nearly double the 35% benchmark from standard of care. The company plans to initiate its pivotal Phase 3 trial (MAPKeeper 301) in mid-2026, with FDA and EMA alignment already secured on trial design.
Immuneering Corporation will host a conference call to discuss updated overall survival and safety data from a Phase 2a clinical trial of atebimetinib + mGnP in first-line pancreatic cancer patients, with 9 months median follow-up.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.